Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease
Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease
复制标题
DOI：
10.1253/circj.72.1193
复制
发表时间：
2008-07-01
影响因子：
3.3
通讯作者：
Ogawa, Hisao
中科院分区：
文献类型：
--
作者：
Sugamura, Koichi;Sugiyama, Seigo;Ogawa, Hisao
背景吡格列酮添加到成功的他汀类药物治疗可能是有益的冠状动脉疾病（CAD）患者无diabetesmellitus.Methods和结果14个人最佳治疗与他汀类药物>6个月被随机分配到吡格列酮或对照组。吡格列酮显著改善胰岛素抵抗，降低高敏C反应蛋白，升高高分子量脂联素和高密度脂蛋白胆固醇水平。颈动脉粥样硬化的超声回声的背向散射积分评估显着增加吡格列酮和相关adiponectin level.Conclusion添加吡格列酮成功的他汀类药物治疗可能是一种有效的治疗策略，冠心病患者。
Background Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus.Methods and Results Fourteen individuals optimally treated with statin for >6 months were randomized to a pioglitazone or control group. Pioglitazone significantly improved insulin resistance, reduced high-sensitivity C-reactive protein, increased high-molecular-weight adiponectin and high-density lipoprotein cholesterol levels. Ultrasound echogenicity of carotid atheroma assessed by integrated backscatter was significantly increased by pioglitazone and correlated with adiponectin levels.Conclusion Adding pioglitazone to successful statin therapy may be an effective therapeutic strategy for patients with CAD.